Bristol Myers Squibb Adopts NVIDIA's Vera Rubin DGX SuperPOD for AI Drug Discovery

Bristol Myers Squibb (BMS) has become the first life sciences company to purchase NVIDIA's next-generation Vera Rubin architecture DGX SuperPOD. This supercomputing system will be used to accelerate the pharmaceutical company's AI-driven drug discovery and development processes. This acquisition highlights the pharmaceutical industry's growing reliance on massive compute power to scale AI models for identifying drug targets and designing therapies. It demonstrates how next-generation hardware can significantly reduce drug preparation times and uncover treatments that might otherwise remain undiscovered. The Vera Rubin-based system offers approximately 10 times the computing power per watt compared to previous generations, addressing the high energy costs of running large AI models. BMS has already utilized AI to reduce clinical trial drug preparation times by 20% to 30%, with expectations to reach a 50% reduction in the coming years.